Lilly to spend up to $1.93B to acquire Boston biopharmaceutical firm
Indianapolis-based Eli Lilly and Co. has agreed to pay up to $1.93 billion to acquire Boston-based biopharmaceutical company Versanis Bio, which focuses on the development of treatments for cardiometabolic diseases, including those related to obesity.... Read More